A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...
Scientists based in Australia and China have identified a pair of pesky enzymes responsible for prolonging prostate cancer – ...
Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without ...
In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback